Hematology (all articles)
RCT: Pegcetacoplan vs. Eculizumab in Paroxysmal Nocturnal Hemoglobinuria
21 Mar, 2021 | 21:32h | UTC
Recent Randomized Trials of Antithrombotic Therapy for Patients With COVID-19: JACC State-of-the-Art Review
21 Mar, 2021 | 21:49h | UTC
Commentary on Twitter
@JACCJournals: We share a systematic summary of #anticcogulation,#antiplatelet, and #fibrinolysis #RCTs in #COVID19. Amazing work by @AzitaTalasaz and a stellar multidisciplinary team! Figs illustrate areas where we’ll have evidence, & the gaps. Link: https://t.co/t4ksxwjAze pic.twitter.com/0Th3OZBXOY
— Behnood Bikdeli (@bbikdeli) March 16, 2021
RCT: Intermediate-dose enoxaparin (1 mg/kg/d) not better than standard-dose prophylactic anticoagulation in patients with Covid-19 admitted to the intensive care unit
19 Mar, 2021 | 08:42h | UTCEditorial: Finding the Optimal Thromboprophylaxis Dose in Patients With COVID-19 – JAMA
Commentary on Twitter
Intermediate-dose prophylactic enoxaparin (1 mg/kg/d) had no effect on a primary composite outcome of adjudicated venous or arterial thrombosis, ECMO, or 30-d mortality vs standard dose enoxaparin among ICU patients w #COVID19 https://t.co/L6UdB31J7V
— JAMA (@JAMA_current) March 18, 2021
Opinion | “’It’s a very special picture.’ Why vaccine safety experts put the brakes on AstraZeneca’s COVID-19 vaccine”
18 Mar, 2021 | 09:14h | UTC‘It’s a very special picture.’ Why vaccine safety experts put the brakes on AstraZeneca’s COVID-19 vaccine – Science (a few articles per month are free)
Related: Update on the safety of COVID-19 Vaccine AstraZeneca (statement and commentaries)
Opinion | “Oxford-AstraZeneca Vaccine Safety: Reports of blood clots after receiving the AstraZeneca COVID-19 vaccine are very likely just background events.”
18 Mar, 2021 | 09:09h | UTCRelated: Update on the safety of COVID-19 Vaccine AstraZeneca (statement and commentaries) AND What is Going on With the AstraZeneca/Oxford Vaccine? – Science Translational Medicine
Platelet tests pre-CABG may safely shorten washout waits, cut costs
16 Mar, 2021 | 01:44h | UTCPlatelet Tests Pre-CABG May Safely Shorten Washout Waits, Cut Costs – TCTMD
[Preprint] RCT: Full-dose/therapeutic anticoagulation provides no benefit in critically ill patients with Covid-19
14 Mar, 2021 | 20:59h | UTCTherapeutic Anticoagulation in Critically Ill Patients with Covid-19-Preliminary Report – medRxiv
Related (results on moderately ill patients): [Not published yet] Full-dose Heparin best for moderate COVID-19 regardless of D-dimer — Data released from ACTIV-4a, ATTACC, and REMAP-CAP trials
Covid-19: European countries suspend use of Oxford-AstraZeneca vaccine after reports of blood clots
12 Mar, 2021 | 08:32h | UTCSee also: More European nations pause AstraZeneca vaccine use as blood clot reports investigated – CNN AND Denmark, Norway and Iceland suspend AstraZeneca COVID shots after blood clot reports – Reuters
Commentary on Twitter
Denmark has temporarily suspended use of the Oxford-AstraZeneca covid-19 vaccine as a precautionary move after reports of blood clots. But the EMA and the UK’s regulatory body say there is no indication that vaccination is linked to thromboembolic events https://t.co/sW8GRqcnLg
— The BMJ (@bmj_latest) March 11, 2021
[Preprint] RECOVERY trial: Convalescent plasma does not improve outcomes in patients admitted to hospital with COVID-19
11 Mar, 2021 | 08:43h | UTC
Commentary on Twitter (thread – click for more)
RECOVERY Pre-print:
Convalescent plasma does not improve survival in patients hospitalised with COVID-19 in this randomised controlled trial involving 11,558 patients:https://t.co/36YZwJNY3Q pic.twitter.com/sKR095n1PC
— Martin Landray (@MartinLandray) March 10, 2021
NIH halts trial of COVID-19 convalescent plasma in emergency department patients with mild symptoms
3 Mar, 2021 | 08:55h | UTC
RCT: Effect of Blinatumomab vs. Chemotherapy in children with high-risk first-relapse B-Cell Acute Lymphoblastic Leukemia
3 Mar, 2021 | 08:19h | UTCEffect of Blinatumomab vs Chemotherapy on Event-Free Survival Among Children With High-risk First-Relapse B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial – JAMA (free for a limited period)
Related study: Effect of Postreinduction Therapy Consolidation With Blinatumomab vs Chemotherapy on Disease-Free Survival in Children, Adolescents, and Young Adults With First Relapse of B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial – JAMA (free for a limited period)
Editorial: Blinatumomab for Treatment of Children With High-risk Relapsed B-Cell Acute Lymphoblastic Leukemia – JAMA (free for a limited period)
M-A: Treatment with convalescent plasma is not associated with better outcomes in patients with Covid-19
28 Feb, 2021 | 21:51h | UTCEditorial: Emerging Lessons From COVID-19 for the US Clinical Research Enterprise
Commentary on Twitter
Just out: Our meta-analysis in @JAMA_current
"Among patients with COVID-19, treatment with convalescent plasma compared with control was not associated with improved survival or other positive clinical outcomes"https://t.co/tRqpd9v67m
— Lars G. Hemkens (@LGHemkens) February 26, 2021
CAR T-cell therapy produces deep, sustained remissions in patients with relapsed myeloma
26 Feb, 2021 | 08:31h | UTCOriginal study: Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma – New England Journal of Medicine
Integrated palliative and oncology care for patients receiving treatment for acute myeloid leukemia
26 Feb, 2021 | 08:25h | UTCOriginal article: Effectiveness of Integrated Palliative and Oncology Care for Patients With Acute Myeloid Leukemia: A Randomized Clinical Trial – JAMA Oncology (link to abstract – $ for full-text)
Randomized trial: Oral Azacitidine maintenance therapy for acute myeloid leukemia in first remission
26 Feb, 2021 | 08:23h | UTCOral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary: Maintenance Oral Azacitidine for Patients With AML in First Remission: QUAZAR AML-001 Trial – The ASCO Post
Editorial: Prophylactic anticoagulation for patients in hospital with covid-19
23 Feb, 2021 | 01:59h | UTCProphylactic anticoagulation for patients in hospital with covid-19 – The BMJ
Related: Full-dose Heparin best for moderate COVID-19 regardless of D-dimer — Data released from ACTIV-4a, ATTACC, and REMAP-CAP trials AND Cohort study: Early initiation of prophylactic anticoagulation linked to reduced mortality in patients admitted to hospital with Covid-19
COVID‐19 convalescent plasma: Interim recommendations from the AABB
19 Feb, 2021 | 02:56h | UTCCOVID‐19 convalescent plasma: interim recommendations from the AABB – Transfusion
News release: AABB panel issues interim recommendations for Covid-19 convalescent plasma use
Defining the optimal total number of chemotherapy courses in younger patients with Acute Myeloid Leukemia: A comparison of 3 vs. 4 courses
19 Feb, 2021 | 02:06h | UTCDefining the Optimal Total Number of Chemotherapy Courses in Younger Patients With Acute Myeloid Leukemia: A Comparison of Three Versus Four Courses – Journal of Clinical Oncology (link to abstract – $ for full-text)
Commentary: Optimal Number of Treatment Courses Explored in Younger Patients with AML – CancerNetwork
Commentary on Twitter
What is the optimal number of chemotherapy courses in younger patients with acute myeloid leukemia (AML)? This study evaluates 3 vs 4 courses https://t.co/peC7Xo3BbX #leusm #JCO pic.twitter.com/OGChNkYS0X
— ASCO Publications (@ASCO_pubs) January 6, 2021
M-A: The effect of convalescent plasma therapy on COVID-19 patient mortality
18 Feb, 2021 | 03:07h | UTCRelated study (not published yet) with conflicting results: RECOVERY trial: No Benefit from convalescent plasma in hospitalized patients with Covid-19 (news release and commentary)
Short review: Acute CV complications of hematopoietic stem cell transplantation
18 Feb, 2021 | 02:40h | UTCAcute CV Complications of Hematopoietic Stem Cell Transplantation – American College of Cardiology
COVID-19: A Hematologist’s Perspective
17 Feb, 2021 | 01:35h | UTCCoronavirus Disease 2019 (COVID-19): A Haematologist’s Perspective – Acta Haematologica
Editorial: A Haematologist’s Guide to Coronavirus Disease 2019: Encyclopaedia or Doorstop?
ASH 2021 guidelines for prevention and treatment of venous thromboembolism in patients with cancer
15 Feb, 2021 | 00:49h | UTC
Cohort study: Early initiation of prophylactic anticoagulation linked to reduced mortality in patients admitted to hospital with Covid-19
15 Feb, 2021 | 01:18h | UTCCommentaries: Preventive blood thinning drugs could reduce COVID hospital deaths – London School of Hygiene & Tropical Medicine AND Preventive blood thinning drugs linked to reduced risk of death in COVID-19 patients – The BMJ AND Expert reaction to a study looking at prophylactic anticoagulants as a treatment for hospitalised patients with COVID-19 – Science Media Centre AND
Commentary on Twitter
Blood thinning drugs are now linked to a reduced risk of death for COVID19 patients. Those given preventive blood thinners (prophylactic anticoagulants) within 24 hours of hospital admission for Covid were less likely to die. New report in the BMJ https://t.co/KQqQ3Zoj8B pic.twitter.com/6wJj8mEucw
— delthia ricks ? (@DelthiaRicks) February 12, 2021
RCT: Among patients with acute MI and anemia, a restrictive transfusion strategy resulted in a noninferior rate of major cardiovascular events compared to a liberal transfusion strategy
10 Feb, 2021 | 01:39h | UTCEffect of a Restrictive vs Liberal Blood Transfusion Strategy on Major Cardiovascular Events Among Patients With Acute Myocardial Infarction and Anemia: The REALITY Randomized Clinical Trial – JAMA (free for a limited period)
Commentary: Restrictive vs. Liberal Blood Transfusion Strategy for MI and Anemia – American College of Cardiology
Commentary on Twitter
Effect of Restrictive vs Liberal Blood Transfusion Strategy on Adults With Myocardial Infarction and Anemia https://t.co/PUtmUj0haw
— JAMA Cardiology (@JAMACardio) February 9, 2021
RCT: Total Body Irradiation vs. Chemotherapy Conditioning in Childhood ALL
9 Feb, 2021 | 00:39h | UTCCommentary: TBI Beats Chemoconditioning for ALL Transplants in Children – Medscape (free registration required)
Commentary on Twitter
Total body irradiation or chemotherapy conditioning in childhood acute lymphoblastic leukemia (ALL) — outcomes suggest there's still a role for TBI https://t.co/ICTC0iEGN8 #leusm #pedonc #pedcsm #JCO pic.twitter.com/xARMBlSeni
— ASCO Publications (@ASCO_pubs) December 26, 2020